Drug intelligence / Profile preview

Yunnan Camellia whitening cream

Development stage: Unknown
Lead developer: Yunnan Botanee Bio-Technology Group
Modality: Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

Yunnan Camellia whitening cream is a new compound topical cream containing Yunnan Camellia, developed by Botanee Bio-Technology CO,LTD, Kunming. It is being investigated for its efficacy and safety in the treatment of melasma/chloasma. The cream is designed to whiten skin, likely by targeting melanin production or distribution, although the specific mechanism of action is not detailed in the provided context.

Other names: New compound whitening cream containing Yunnan Camellia

Targets

TYR (Tyrosinase)

Beyond the preview

Go deeper on Yunnan Camellia whitening cream.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yunnan Camellia whitening cream.

Explore the full profile